Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCH 527123 dose-ranging safety study in moderate to severe COPD
2005-004287-23Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of navarixin in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Merck & Co. Primary endpoints: Adverse events, Change from baseline in absolute peripheral blood neutrophil count and 1 more. Started Aug 2006; status: terminated.
02
Drugs
navarixin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2005-004287-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004287-23.